{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:54:15Z","timestamp":1781592855923,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["FAPESP-12\/51215-4"],"award-info":[{"award-number":["FAPESP-12\/51215-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.biopha.2018.01.027","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T10:35:10Z","timestamp":1519382110000},"page":"237-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects"],"prefix":"10.1016","volume":"99","author":[{"given":"Jana\u00edna","family":"Peixoto-da-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrana K.","family":"Calgarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiucha R.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Palmeira-dos-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya S.","family":"Smaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo J.S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando V.","family":"Pericole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"da Silva S. Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.O.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bincoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.01.027_bib0005","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"142","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.biopha.2018.01.027_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.01.027_bib0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2018.01.027_bib0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/stem.180399","article-title":"Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia","volume":"18","author":"Kabarowski","year":"2000","journal-title":"Stem Cells"},{"key":"10.1016\/j.biopha.2018.01.027_bib0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1349-7006.2010.01584.x","article-title":"Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells","volume":"101","author":"Naka","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2018.01.027_bib0030","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1128\/MCB.15.10.5531","article-title":"Structural and signaling requirements for BCR\/ABL-mediated transformation and inhibition of apoptosis","volume":"15","author":"Cortez","year":"1995","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2018.01.027_bib0035","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1084\/jem.179.6.1855","article-title":"Negative regulation of p120 GAP GTPase promoting activity by p210bcr\/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth","volume":"179","author":"Skorski","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2018.01.027_bib0040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappa B activation in BCR\/ABL-mediated transformation","volume":"12","author":"Reuther","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2018.01.027_bib0045","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR\/ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2018.01.027_bib0050","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3K\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2018.01.027_bib0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol-3 kinase\/Akt pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2018.01.027_bib0060","doi-asserted-by":"crossref","first-page":"25227","DOI":"10.1074\/jbc.M114.554881","article-title":"Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of Rapamycin) by IkB kinase \u03b1 (IKK\u03b1)","volume":"19","author":"Dan","year":"2014","journal-title":"J. Biol Chem."},{"issue":"4","key":"10.1016\/j.biopha.2018.01.027_bib0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/cdd.2012.153","article-title":"Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells","volume":"20","author":"Singh","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2018.01.027_bib0070","first-page":"63","article-title":"FoxO tumor supressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis","volume":"1785","author":"Jagani","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2018.01.027_bib0075","first-page":"857","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"96","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.01.027_bib0080","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Cardone","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.biopha.2018.01.027_bib0085","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1038\/sj.onc.1204984","article-title":"The protein kinase PKB\/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change","volume":"20","author":"Yamaguchi","year":"2001","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.biopha.2018.01.027_bib0090","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistence leukemia by DNA PCR","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2018.01.027_bib0095","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.01.027_bib0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1053\/shem.2003.50047","article-title":"Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies","volume":"40","author":"Tipping","year":"2003","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.biopha.2018.01.027_bib0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/leu.2013.184","article-title":"Multifaceted roles of GSK-3 and Wnt\/\u03b2-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention","volume":"28","author":"McCubrey","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2018.01.027_bib0110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/cpr.12092","article-title":"GSK-3\u03b2 inhibition promotes early engraftment of ex vivo-expanded haematopoietic stem cells","volume":"47","author":"Dolnikov","year":"2014","journal-title":"Cell Prolif."},{"key":"10.1016\/j.biopha.2018.01.027_bib0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/ni1006-1021","article-title":"Hematopoietic stem cell biology: too much of a Wnt thing","volume":"7","author":"Trowbridge","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2018.01.027_bib0120","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK-3\u03b2 promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Reddiconto","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2018.01.027_bib0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/mp.2015.4","article-title":"Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics","volume":"20","author":"Alda","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2018.01.027_bib0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1189\/jlb.0608388","article-title":"Lithium and hematology: established and proposed uses","volume":"85","author":"Focosi","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.biopha.2018.01.027_bib0135","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important therapeutic targets in chronic myelogenous leukemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2018.01.027_bib0140","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1172\/JCI31691","article-title":"Treatment for chronic myelogenous leukemia: the long road to imatinib","volume":"117","author":"Hunter","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.01.027_bib0145","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.01.027_bib0150","series-title":"The Hematopoietic Colony-Stimulating Factors","first-page":"187","article-title":"The bioassay of colony-stimulating factors","author":"Metcalf","year":"1984"},{"key":"10.1016\/j.biopha.2018.01.027_bib0155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/nature07284","article-title":"Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy","volume":"455","author":"Wang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.01.027_bib0160","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","article-title":"BCR\/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability","volume":"21","author":"Skorski","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2018.01.027_bib0165","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2018.01.027_bib0170","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.28261","article-title":"Molecular-targeted agents combination therapy for cancer: developments and potentials","volume":"134","author":"Li","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2018.01.027_bib0175","doi-asserted-by":"crossref","first-page":"e1002323","DOI":"10.1371\/journal.pcbi.1002323","article-title":"Prediction of drug combinations by integrating molecular and pharmacological data","volume":"12","author":"Zhao","year":"2011","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.biopha.2018.01.027_bib0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.cdd.4400525","article-title":"Apoptosis without caspase: an inefficient molecular guillotine?","volume":"6","author":"Borner","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2018.01.027_bib0185","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biopha.2018.01.027_bib0190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0165-6147(03)00206-2","article-title":"Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes","volume":"24","author":"Jope","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2018.01.027_bib0195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.leukres.2011.11.013","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway","volume":"36","author":"Mirlashari","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2018.01.027_bib0200","first-page":"248","article-title":"Lithium inhibits carcinoid cell growth in vitro","volume":"2","author":"Greenblatt","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.biopha.2018.01.027_bib0205","first-page":"1","article-title":"Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth","volume":"34","author":"Azoulay-Alfaguter","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2018.01.027_bib0210","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","article-title":"Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide","volume":"120","author":"Goussetis","year":"2012","journal-title":"Blood"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217354410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217354410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:12:51Z","timestamp":1781590371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217354410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":42,"alternative-id":["S0753332217354410"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.01.027","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}